Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Top Cited Papers
- 11 June 2016
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 39 (7), 1115-1122
- https://doi.org/10.2337/dc16-0542
Abstract
Type 2 diabetes mellitus causes excessive morbidity and premature cardiovascular (CV) mortality. Although tight glycemic control improves microvascular complications, its effects on macrovascular complications are unclear. The recent publication of the EMPA-REG OUTCOME study documenting impressive benefits with empagliflozin (a sodium–glucose cotransporter 2 [SGLT2] inhibitor) on CV and all-cause mortality and hospitalization for heart failure without any effects on classic atherothrombotic events is puzzling. More puzzling is that the curves for heart failure hospitalization, renal outcomes, and CV mortality begin to separate widely within 3 months and are maintained for >3 years. Modest improvements in glycemic, lipid, or blood pressure control unlikely contributed significantly to the beneficial cardiorenal outcomes within 3 months. Other known effects of SGLT2 inhibitors on visceral adiposity, vascular endothelium, natriuresis, and neurohormonal mechanisms are also unlikely major contributors to the CV/renal benefits. We postulate that the cardiorenal benefits of empagliflozin are due to a shift in myocardial and renal fuel metabolism away from fat and glucose oxidation, which are energy inefficient in the setting of the type 2 diabetic heart and kidney, toward an energy-efficient super fuel like ketone bodies, which improve myocardial/renal work efficiency and function. Even small beneficial changes in energetics minute to minute translate into large differences in efficiency, and improved cardiorenal outcomes over weeks to months continue to be sustained. Well-planned physiologic and imaging studies need to be done to characterize fuel energetics–based mechanisms for the CV/renal benefits.Keywords
This publication has 42 references indexed in Scilit:
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Metabolic Mechanisms in Heart FailureCirculation, 2007
- Diabetic Cardiomyopathy RevisitedCirculation, 2007
- Fuel Metabolism in StarvationAnnual Review of Nutrition, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Myocardial Substrate Metabolism in the Normal and Failing HeartPhysiological Reviews, 2005
- What Causes Sudden Death in Heart Failure?Circulation Research, 2004
- Blood ketone bodies in congestive heart failureJournal of the American College of Cardiology, 1996
- Blood Ketone Bodies in Congestive Heart FailureJournal of the American College of Cardiology, 1996
- Metabolic fuels along the nephron: Pathways and intracellular mechanisms of interactionKidney International, 1986